drugset / Trial / NCT04934228
Mitigating the Pro-inflammatory Phenotype of Obesity
RandomizedParallel-groupDouble-blindOther
Summary
The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clonidine | Other / unclassified | 0.1 mg | Oral |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | Oral |